Growth hormone secretion declines by approximately 14% per decade after age 30 in men, with the steepest decline occurring between ages 40 and 60. This age-related GH decline — sometimes called somatopause — contributes to increased visceral fat, reduced lean muscle mass, decreased bone density, and impaired recovery. Sermorelin, a synthetic analogue of growth hormone-releasing hormone (GHRH), stimulates the pituitary to produce its own GH rather than replacing it exogenously.
Men over 40 experience a convergence of hormonal changes: declining testosterone, declining GH, and rising cortisol. These changes are synergistic — low GH impairs the anabolic effects of testosterone, and low testosterone reduces GH pulse amplitude. Sermorelin addresses the GH component of this hormonal shift while preserving the pituitary's natural feedback regulation, which distinguishes it from exogenous HGH therapy.
Research protocols for men over 40 typically use Sermorelin at 200–300 mcg administered subcutaneously before sleep, 5–7 nights per week. Some protocols use a higher starting dose of 300–500 mcg during the first 4–8 weeks (loading phase), then reduce to a maintenance dose. Men over 40 may have a blunted pituitary response compared to younger subjects, which is why some protocols use higher doses or combine Sermorelin with a GHRP like Ipamorelin.
Improved sleep quality, particularly deeper slow-wave sleep. Mild increases in energy and recovery speed.
IGF-1 levels begin rising. Subtle improvements in body composition — slight reduction in visceral fat, mild increase in lean mass.
More pronounced body composition changes. Improved skin elasticity and joint comfort reported in research subjects.
Peak body composition effects. IGF-1 levels stabilize at new baseline. Some protocols reduce dose at this point.
Sermorelin stimulates the pituitary to produce its own GH, preserving natural feedback regulation and pulsatile release patterns. Exogenous HGH bypasses this regulation and suppresses endogenous production. Most anti-aging researchers prefer Sermorelin for long-term use due to its more physiological mechanism.
Most research subjects report improved sleep quality within 2–4 weeks. Measurable IGF-1 increases are typically seen at 4–8 weeks. Body composition changes (reduced fat, increased lean mass) are generally observed after 8–16 weeks of consistent use.
The combination is commonly studied in anti-aging research. Testosterone and GH have synergistic effects on body composition — testosterone supports muscle protein synthesis while GH promotes lipolysis and IGF-1 production. The two can be used concurrently without significant adverse interactions.
Research protocols typically use 200–300 mcg before sleep, 5–7 nights per week. Men with a blunted pituitary response may use 300–500 mcg. Dose should be titrated based on IGF-1 response — target IGF-1 levels in the upper quartile of the age-appropriate reference range.
Purgo Labs provides research-grade peptides with independent third-party COAs and >99% purity verification.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.